Inkine Pharmaceutical Co Inc Watch

from 8-K 1 page Material contract

from 8-K ~10 pages Material contract

from 8-K ~5 pages Material contract

from 8-K 1 page Material contract

from 8-K 5 pages Inkine Pharmaceutical Company, Inc. Long-Term Incentive Plan 1. Plan Objective

from 10-Q 2 pages Employment Agreement

from 10-Q 2 pages Employment Agreement

from 10-Q 9 pages Employment Agreement

from 10-Q ~10 pages Equity Compensation Plan Inkine 06-30-2004

from 10-K 1 page <page> Amendment to Employment Agreement Amendment Dated November 20, 2003 to Employment Agreement Dated as of December 1, 2000 Between Inkine Pharmaceutical Company, Inc. a New York Corporation ("Employer") and Martin Rose, M.D., J.D. ("Employee"). Employer and Employee Are Party to the Employment Agreement Referred to Above (The "Agreement"). the Employer and Employee Have Agreed to Certain Changes to the Agreement, Specifically Changes With Respect to Base Compensation and Severance. Now Therefore, in Consideration of the Premises and Intending to Be Legally Bound Hereby, Employer and Employee Hereby Agree as Follows: 1. the First Sentence of Section 1.5 of the Agreement Is Hereby Amended to Substitute "$243,000" for "$225,000." 2. Section 1.7(c) Shall Be Inserted and the Agreement Shall Be Amended to Read, in Its Entirety, as Follows: "(C) the Employer Shall Continue to Provide Health Insurance Benefits Comparable to Such Benefits in Effect at the Date of Termination for a Period of Twelve (12) Months From the Date of Such Termination." 3. Except as Set Forth Above, the Agreement Shall Remain in Full Force and Effect as Currently Written. in Witness Whereof, the Undersigned Have Executed This Amendment to the Employment Agreement as of the Date First Above Written. Inkine Pharmaceutical Company, Inc. By: /S/ Leonard S. Jacob, M.D., PH.D. Leonard S. Jacob, M.D., PH.D. Chairman and Chief Executive Officer Martin Rose, M.D., J.D. /S/ Martin Rose, M.D., J.D

from 10-K ~10 pages Material contract

from 10-K 1 page <page> Amendment to Employment Agreement Amendment Dated November 20, 2003 to Employment Agreement Dated as of November 2, 1998 Between Inkine Pharmaceutical Company, Inc. a New York Corporation ("Employer") and Robert F. Apple ("Employee"). Employer and Employee Are Party to the Employment Agreement Referred to Above (The "Agreement"). the Employer and Employee Have Agreed to Certain Changes to the Agreement, Specifically Changes With Respect to Base Compensation and Severance. Now Therefore, in Consideration of the Premises and Intending to Be Legally Bound Hereby, Employer and Employee Hereby Agree as Follows: 1. the First Sentence of Section 1.5 of the Agreement Is Hereby Amended to Substitute "$300,000" for "$150,000." 2. Section 1.7(a) of the Agreement Shall Be Amended to Read, in Its Entirety, as Follows: "(A) if Employer Terminates This Agreement, Other Than for "Cause" Pursuant to Section 4.3 Hereof at Any Time During the Employment Term, Employer Shall Pay to Employee an Amount Equal to 150% of Employee's Base Annual Salary in Effect at the Date of Such Termination." 3. Section 1.7(d) Shall Be Inserted and the Agreement Shall Be Amended to Read, in Its Entirety, as Follows: "(D) the Employer Shall Continue to Provide Health Insurance Benefits Comparable to Such Benefits in Effect at the Date of Termination for a Period of Eighteen (18) Months From the Date of Such Termination." 4. Except as Set Forth Above, the Agreement Shall Remain in Full Force and Effect as Currently Written. in Witness Whereof, the Undersigned Have Executed This Amendment to the Employment Agreement as of the Date First Above Written. Inkine Pharmaceutical Company, Inc. By: /S/ Leonard S. Jacob, M.D., PH.D. Leonard S. Jacob, M.D., PH.D. Chairman and Chief Executive Officer Robert F. Apple. /S/ Robert F. Apple

from 10-K 1 page <page> Amendment to Employment Agreement Amendment Dated November 20, 2003 to Employment Agreement Dated as of November 6, 1997, as Amended on November 4, 1999, Between Inkine Pharmaceutical Company, Inc. a New York Corporation ("Employer") and Leonard S. Jacob, M.D., PH.D. ("Employee"). Employer and Employee Are Party to the Employment Agreement Referred to Above (The "Agreement"). the Employer and Employee Have Agreed to Certain Changes to the Agreement, Specifically Changes With Respect to Base Compensation and Severance. Now Therefore, in Consideration of the Premises and Intending to Be Legally Bound Hereby, Employer and Employee Hereby Agree as Follows: 1. the First Sentence of Section 1.5 of the Agreement Is Hereby Amended to Substitute "$420,000" for "$290,000." 2. Section 1.7(d) Shall Be Inserted and the Agreement Shall Be Amended to Read, in Its Entirety, as Follows: "(D) the Employer Shall Continue to Provide Health Insurance Benefits Comparable to Such Benefits in Effect at the Date of Termination for a Period of Two Years From the Date of Such Termination." 3. Except as Set Forth Above, the Agreement Shall Remain in Full Force and Effect as Currently Written. in Witness Whereof, the Undersigned Have Executed This Amendment to the Employment Agreement as of the Date First Above Written. Inkine Pharmaceutical Company, Inc. By: /S/ Robert F. Apple Robert F. Apple Chief Operating and Financial Officer Leonard S. Jacob, M.D., PH.D. /S/ Leonard S. Jacob, M.D., PH.D

from 10-Q ~10 pages Severance Agreement

from 10-Q 1 page Amendment to Employment Agreement

from 10-K405 ~10 pages Employment Agreement

from 8-K ~10 pages Material contract

from 8-K ~10 pages Material contract

from 8-K ~10 pages Material contract

from 8-K ~10 pages Material contract